Cargando…

Anti-angiogenic therapies in the management of glioblastoma

Angiogenesis is a central feature of glioblastoma (GBM), with contribution from several mechanisms and signaling pathways to produce an irregular, poorly constructed, and poorly connected tumor vasculature. Targeting angiogenesis has been efficacious for disease control in other cancers, and given t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schulte, Jessica D., Aghi, Manish K., Taylor, Jennie W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10631456/ https://www.ncbi.nlm.nih.gov/pubmed/32389001 http://dx.doi.org/10.21037/cco.2020.03.06

Ejemplares similares

Interactions Between Anti-Angiogenic Therapy and Immunotherapy in Glioblastoma
por: Jain, Saket, et al.
Publicado: (2022)

Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy
por: Kwiatkowski, Sam C., et al.
Publicado: (2017)

Revisiting anti-angiogenic therapy for recurrent glioblastoma
por: Peters, Katherine B.
Publicado: (2019)

Mechanisms of Tumor Development and Anti-angiogenic Therapy in Glioblastoma Multiforme
por: Onishi, Manabu, et al.
Publicado: (2013)

Exploring the Past, Present, and Future of Anti-Angiogenic Therapy in Glioblastoma
por: Zhang, Ashley B., et al.
Publicado: (2023)

Glioblastoma-Specific Strategies of Vascularization: Implications in Anti-Angiogenic Therapy Resistance
por: Buccarelli, Mariachiara, et al.
Publicado: (2022)

Metabolic Drivers of Invasion in Glioblastoma
por: Garcia, Joseph H., et al.
Publicado: (2021)

Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma
por: Obad, Nina, et al.
Publicado: (2017)

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy
por: Castro, B A, et al.
Publicado: (2017)

Metabolic Barriers to Glioblastoma Immunotherapy
por: Choudhary, Nikita, et al.
Publicado: (2023)

MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma
por: Talati, Pratik, et al.
Publicado: (2021)

Endoglin (CD105) and proliferation index in recurrent glioblastoma treated with anti-angiogenic therapy
por: Bastos, António G. P., et al.
Publicado: (2022)

Angiogenic signaling pathways and anti-angiogenic therapy for cancer
por: Liu, Zhen-Ling, et al.
Publicado: (2023)

Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma
por: Guarnaccia, Laura, et al.
Publicado: (2021)

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
por: Verhoeff, Joost JC, et al.
Publicado: (2009)

Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma
por: Jeon, Hanwool, et al.
Publicado: (2023)

Nephrotoxicity of Anti-Angiogenic Therapies
por: Van Wynsberghe, Margaux, et al.
Publicado: (2021)

The promise of anti-angiogenic cancer therapy
por: Oehler, M K, et al.
Publicado: (2000)

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme
por: Zheng, Shuhua, et al.
Publicado: (2021)

Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in Glioblastoma
por: Angara, Kartik, et al.
Publicado: (2017)

Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma
por: Joshkon, Ahmad, et al.
Publicado: (2022)

Anti-angiogenic therapy for ovarian cancer
por: García García, Yolanda, et al.
Publicado: (2020)

Metabolic changes and anti-tumor effects of a ketogenic diet combined with anti-angiogenic therapy in a glioblastoma mouse model
por: Maeyama, Masahiro, et al.
Publicado: (2021)

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)
por: Demeure, Kevin, et al.
Publicado: (2016)

Anti-Angiogenic Therapy Induces Integrin-Linked Kinase 1 Up-Regulation in a Mouse Model of Glioblastoma
por: Verpelli, Chiara, et al.
Publicado: (2010)

Biomarkers for Anti-Angiogenic Therapy in Cancer
por: Wehland, Markus, et al.
Publicado: (2013)

Anti-angiogenic therapies in brain metastases
por: Berghoff, Anna S., et al.
Publicado: (2018)

Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme
por: Kang, Wonyoung, et al.
Publicado: (2015)

Protein disulfide-isomerase A4 confers glioblastoma angiogenesis promotion capacity and resistance to anti-angiogenic therapy
por: Tu, Zewei, et al.
Publicado: (2023)

Immunotherapy Resistance in Glioblastoma
por: Wang, Elaina J., et al.
Publicado: (2021)

3352 Surgical Adjuvant of Immunomodulatory Gene Circuits for Treatment of Glioblastoma
por: Spatz, Jordan Matthew, et al.
Publicado: (2019)

Modulation of Angiogenic and Inflammatory Response in Glioblastoma by Hypoxia
por: Murat, Anastasia, et al.
Publicado: (2009)

ANGI-05 PATHOGENESIS OF RESISTANCE (MIMICRY AND CO-OPTION) TO ANTI-ANGIOGENIC TREATMENT FOR GLIOBLASTOMA
por: Takano, Shingo, et al.
Publicado: (2019)

Recent Advances in Anti-Angiogenic Therapy of Cancer
por: Samant, Rajeev S., et al.
Publicado: (2011)

Biomarkers in Tumor Angiogenesis and Anti-Angiogenic Therapy
por: Pircher, Andreas, et al.
Publicado: (2011)

Future options of anti-angiogenic cancer therapy
por: Cao, Yihai
Publicado: (2016)

Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer
por: Nienhüser, Henrik, et al.
Publicado: (2017)

Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers
por: Olejarz, Wioletta, et al.
Publicado: (2020)

Trends and Challenges in Tumor Anti-Angiogenic Therapies
por: Jászai, József, et al.
Publicado: (2019)

Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
por: Haibe, Yolla, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1nlca7a141k7mrdqookgag3gm5